The Access to Medicine Index is a very important project. What gets measured, gets done.
New online: the first Antimicrobial Resistance Benchmark
The 2018 Antimicrobial Resistance Benchmark is now online. It is the first report to assess how pharmaceutical companies are tackling rising rates of drug-resistant infections. The Benchmark finds evidence of good practice in multiple areas – the task now is to expand them to more products.
Read more >>
Watch the live launch at the WEF >>
21 Feb 2018
09 Feb 2018
25 Jan 2018
24 Jan 2018
Now published: first independent comparison of pharma companies’ efforts to address drug-resistant infections
24 Jan 2018
12 Oct 2017
05 Oct 2017
24 Aug 2017
Access to medicine: a material issue for investors
Investors engage with the Foundation for insight into our analysis of the pharma sector, including into governance structures, R&D and pricing strategies.
The foundation on Twitter
“To improve access, we believe pharmaceutical companies need to focus on how
they deploy their products, and, as global citizens, collaborate on the development of strong health systems.”
Jayasree K. Iyer, Executive Director, Access to Medicine Foundation.
The Access to Medicine Foundation and its publications are funded by